A 72-year-old woman on warfarin for atrial fibrillation (INR 4.2 today) presents with acute-onset left-sided weakness and speech difficulty. CT head shows a 45 mL right frontal lobe hemorrhage with 8 mm midline shift. Her blood pressure is 185/105 mmHg. Which of the following is the most appropriate immediate management step?

Explanation

## Clinical Context: Anticoagulation-Associated ICH **Key Point:** Warfarin-associated ICH (INR >4) requires **urgent reversal of anticoagulation** to prevent hematoma expansion, which is the leading cause of poor outcome in the first 24 hours. ## Management Algorithm for Anticoagulation-Associated ICH ```mermaid flowchart TD A["Anticoagulation-Associated ICH<br/>(INR >4)"]:::outcome --> B{"Hematoma size & location?"}:::decision B -->|"Small, stable<br/>No mass effect"| C["Reverse anticoagulation<br/>FFP + Vitamin K"]:::action B -->|"Large >30 mL<br/>or midline shift"| D["Reverse anticoagulation<br/>FFP + Vitamin K"]:::action D --> E["Neurosurgical consultation<br/>Consider evacuation"]:::action C --> F["BP control SBP 140-160"]:::action E --> G{"Surgical candidate?"}:::decision G -->|"Yes: GCS >5, no coagulopathy"| H["Hematoma evacuation"]:::action G -->|"No: poor prognosis"| I["Medical management"]:::action F --> J["ICU monitoring"]:::action ``` ## Anticoagulation Reversal Strategy | Agent | Mechanism | Dosing | Onset | |-------|-----------|--------|-------| | **Vitamin K (phytonadione)** | Cofactor for factors II, VII, IX, X | 10 mg IV slow infusion | 12–24 hours (slow) | | **Fresh Frozen Plasma (FFP)** | Direct factor replacement | 10–15 mL/kg (usually 3–4 units) | 15–30 min (rapid) | | **Prothrombin Complex Concentrate (PCC)** | Concentrated factors II, VII, IX, X | 25–50 units/kg | 15 min (fastest) | **High-Yield:** FFP + Vitamin K is the standard combination for warfarin reversal in ICH. FFP provides immediate factor replacement while Vitamin K works over hours. **PCC is preferred if available** (faster, less volume overload) but FFP is widely available in Indian hospitals. ## Why This Patient Needs Urgent Reversal 1. **INR 4.2** — significantly elevated, high risk of ongoing hematoma expansion 2. **45 mL hemorrhage** — large, already causing mass effect (8 mm midline shift) 3. **Frontal lobe location** — potentially evacuable if patient remains surgical candidate 4. **Expansion risk**: Anticoagulation-associated ICH expands in ~50% of cases in first 24 hours without reversal ## Blood Pressure Management **Clinical Pearl:** In anticoagulation-associated ICH, the priority is **reversal first, then BP control**. Target SBP 140–160 mmHg (not <140, which may impair cerebral perfusion). Use labetalol or nicardipine for titratable control. **Key Point:** Aggressive BP lowering (<140 mmHg) in acute ICH increases risk of perihematomal ischemia — the INTERACT-2 trial showed no benefit of ultra-intensive BP control (<140 mmHg) and potential harm. ## Neurosurgical Consultation After anticoagulation reversal, neurosurgical evaluation is needed to assess candidacy for hematoma evacuation. Factors favoring surgery: - GCS >5 - No coagulopathy (after reversal) - Accessible location (frontal lobe is favorable) - Age and comorbidities [cite:Harrison 21e Ch 435; Stroke Council Guidelines 2015]